Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
inFerring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle…
Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle…
Ferring receives U.S. FDA approval for REBYOTA™ (fecal microbiota, live-jslm) – A…
…
Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in…
…
Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-based…
Ferring announces ground-breaking and inclusive family building benefits package for all its…
This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.
OKCette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.
OKIk bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals
OKEz az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.
OKTa strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.
OKЭта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.
OK